Accession ID Name Pfam Type
PF15782 GREB1 N-terminal domain domain

GREB1 (gene regulated by estrogen in breast cancer 1) was first identified as an estrogen-regulated gene expressed in breast cancer [1]. Its exact function is not known but its expression is regulated by the coordinated binding of estrogen-receptors to distal sites interacting with Pol II to activate gene transcription from core promoters located at a considerable distance from the greb1 gene [2,3,4]. It acts as a regulator of hormone-dependent cancer growth in breast, ovarian and prostate cancers [3,4,5,6]. This entry represents a N-terminal domain whose function is not yet known. Structure predictions suggest that it may have an alpha-beta fold.

Pfam Range: 49-200 DPAM-Pfam Range: 106-126,141-213
Uniprot ID: A0A673BWA3
Pfam Range: 1-145 DPAM-Pfam Range: 51-70,87-105,121-141
Uniprot ID: S4RYV8
Pfam Range: 1-147 DPAM-Pfam Range: 52-74,87-111,118-143
Uniprot ID: A0A7L2E4Q4

References

1: PDZK1 and GREB1 are estrogen-regulated genes expressed in hormone-responsive breast cancer. Ghosh MG, Thompson DA, Weigel RJ; Cancer Res. 2000;60:6367-6375. PMID:11103799

2: GREB 1 is a critical regulator of hormone dependent breast cancer growth. Rae JM, Johnson MD, Scheys JO, Cordero KE, Larios JM, Lippman ME; Breast Cancer Res Treat. 2005;92:141-149. PMID:15986123

3: GREB1 is a novel androgen-regulated gene required for prostate cancer growth. Rae JM, Johnson MD, Cordero KE, Scheys JO, Larios JM, Gottardis MM, Pienta KJ, Lippman ME; Prostate. 2006;66:886-894. PMID:16496412

4: Long-range activation of GREB1 by estrogen receptor via three distal consensus estrogen-responsive elements in breast cancer cells. Sun J, Nawaz Z, Slingerland JM; Mol Endocrinol. 2007;21:2651-2662. PMID:17666587

5: GREB1 is an estrogen receptor-regulated tumour promoter that is frequently expressed in ovarian cancer. Hodgkinson K, Forrest LA, Vuong N, Garson K, Djordjevic B, Vanderhyden BC; Oncogene. 2018;37:5873-5886. PMID:29973689

6: GREB1 amplifies androgen receptor output in human prostate cancer and contributes to antiandrogen resistance. Lee E, Wongvipat J, Choi D, Wang P, Lee YS, Zheng D, Watson PA, Gopalan A, Sawyers CL; Elife. 2019; [Epub ahead of print] PMID:30644358